• California-based sustainable bed and bath comfort brand Coyuchi Inc. has established its brand not only on the luxury of its products, but the organic sourcing of the textiles it uses
• Consumers increasingly are scrutinizing the sourcing of their home decor products in search of evidence they are friendly to earth’s climate and responsibly produced
• Coyuchi’s management team brings experience in corporate function and an enthusiasm for sustainability in the company’s sourcing and partnerships
• The company launched a Reg A+ investment offering last year that led to a capital raise topping $1 million

One significant driver in choosing fabrics for home decor these days is determining where they are sourced. “Homeowners, more than ever, are paying close attention to what their home fabrics are made of and where they have come from,” a recent report drawing on decorator’s insights states (https://ibn.fm/eKQUm).

Luxury bed, bath, and apparel product company Coyuchi devotes its corporate purpose to being “responsible beyond the thread” — using cotton and linen certified to the Global Organic Textile Standard (“GOTS”) respected as the most rigorous around the world, and extending beyond that to product use and recycling considerations.

“When Coyuchi was founded 30 years ago, the original founder — her goal was to bring organic cotton into the textile industry for home goods, and we’ve really taken that mission to heart,” Coyuchi President and CEO Eileen Mockus said during a recent interview with the Bell2Bell podcast (https://ibn.fm/GGr0I). “And (we) are finding ways to expand on it and continuing to look at the whole process of what we do.”

In addition to Sejal Solanki (Chief Marketing Officer), Marcus Chung (Chief Operating Officer), Gabriela Bermudez (Controller), and Priyadarshi Sinha (VP of Technology), Mockus leads an experienced team of sustainable fashion design enthusiasts.

Design Director Whitney Thornburg arrived in the industry from an education career where she developed and taught fashion design curriculum in sustainable practices and creating circular systems. After two years-long seasons working for a San Francisco clothing label, she joined Coyuchi in 2019.

Director of Sustainability and Sourcing Margot Lyons played a direct role in Coyuchi’s achievement of full circularity — a term describing the use of design, recycling, reuse, remanufacturing and refurbishment to create a closed loop system that eliminate waste and maximize the reuse of resources (https://ibn.fm/LEIn9). Lyons has been with the company for over a decade as it has built a wide reputation for luxury and responsibility, working with Coyuchi’s strategic partners to ensure the company’s standards for product sustainability are achieved. The effort led to Coyuchi’s first fully circular product — the Full Circle Recycled Cotton Blanket and Throw — in 2021.

Brand Marketing Director Julie Wells and Director of Operations Izzie Ali have similarly brought a drive for sustainable and eco-friendly business practices to the company with their arrivals during the past year, drawing on international educations as well as their experiences in North American industry.

Together, Coyuchi continues to maintain and expand their earth-friendly brand. The company’s Impact Report 2021 outlined Coyuchi’s goals for achieving Net Zero emissions by 2025 and becoming Net Positive by 2030, working under the direction of the Coyuchi Climate Council and in collaboration with a network of partners and non-profits around the world (https://ibn.fm/XxLqw).

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more
• The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs
• Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more.

Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and shown improved triglyceride and cholesterol levels (https://ibn.fm/5micP). The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (“CBD”), aligned with other study work pointing to CBD’s known anti-inflammatory and antioxidant properties. Lexaria is pleased that relatively low dosages of DehydraTECH-CBD seem to support real improvements in the lab animals’ day-to-day health and find encouragement in the positive findings from its first diabetes study.

In addition to DIAB-A22-1, some of Lexaria’s previous R&D programs include:

• HYPER-A21-1 – a rodent study demonstrating significant enhancement in CBD delivery using DehydraTECH with more CBD delivered into the bloodstream and brain tissue
• HYPER-A21-2 – a rodent study demonstrating the strongest CBD absorption results ever recorded
• HYPER-H21-1 – Human clinical study evidencing a rapid and sustained drop in blood pressure with excellent tolerability using DehydraTECH-CBD
• HYPER-H21-2 – Human clinical Hypoxic Pulmonary Vasoconstriction study with evidence of up to a 23% decrease in blood pressure confirming a reduction in arterial stiffness
• HYPER-H21-3 – Human clinical Pulmonary Hypertension Clinical Study intended to support Lexaria’s plan to seek FDA approvals
• HYPER-H21-4 – Human clinical study exhibiting exceptional safety and tolerability with statistically significant evidence of lowered blood pressure in patients and showed great absorption levels and potential novel mechanism of action in reducing blood pressure
• VIRAL-C21-3 – In vitro screening assay completed using primate cell line, VERO-E6, determining that remdesivir and ebastine processed with DehydraTECH were effective in inhibiting the COVID-19 virus
• VIRAL-A20-2 – A rodent study showing a three-fold increase in oral delivery of anti-viral drugs
• VIRAL-MC21-1 – research concluded that DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity or change in chemical structure
• VIRAL-A20-3 – A rodent study demonstrating significant enhancement in anti-viral drug delivery using DehydraTECH-enabled Colchicine with possible benefits of treating COVID-19 and mRNA vaccine side effects
• NIC-A21-1 – DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x and 20x faster than controls, with peak levels achieved 10x higher than controls
• PDE5-A21-1 – DehydraTECH-sildenafil delivered 74% more drug at 4 minutes than the control
• EPIL-A21-1 – DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R)

Since 2014, Lexaria has been developing its patented DehydraTECH technology, which has yielded 28 granted patents and many more pending in countries worldwide. DehydraTECH’s evidenced benefits include the improved speed of onset, increased bioavailability, increased brain absorption, and reduced drug administration costs. As more research becomes available from Lexaria’s ongoing R&D programs, the company will provide updates.

Lexaria operates four subsidiary companies, focusing on different commercial opportunities in their respective industries:

• Lexaria Pharmaceutical Corp. investigates new products for hypertension, antiviral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes
• Lexaria Nicotine LLC investigates oral non-combusted tobacco-derived nicotine product formats
• Lexaria Hemp Corp. pursues business-to-business opportunities with cannabinoids
• Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization

Lexaria sub-licenses the company’s DehydraTECH technology for the delivery of fat-soluble active molecules and drugs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”)
• This milestone is the culmination of years of meticulous planning and execution
• The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking a key milestone in its GBM clinical study. Considered a potentially pivotal global trial for the company, the study seeks to evaluate Berubicin, the company’s lead drug candidate, for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

In what the CEO, John Climaco, regarded as an “encouraging enrollment pace,” CNS is on track to conduct its planned interim analysis set for mid-2023. This recent enrollment of the first patient in Spain is a major highlight of this progress (https://ibn.fm/peyQi).

“We continue to rapidly build momentum with patient enrollment across our clinical trial sites in Europe,” noted Climaco.

“We sincerely appreciate the institutions, clinicians and staff that are contributing to the conduct of this trial, and are extremely grateful to the patients that choose to participate,” he added.

In 2007, a prior developer released partial results from its Phase 1 clinical trial of Berubicin among patients with primary CNS malignancies (https://ibn.fm/VwP1V). Results, which showed 44% of patients exhibiting a clinical response, demonstrated a durable complete response, along with a stable disease in heavily pretreated patients. Results from this study would set the stage for subsequent research by CNS, leading up to the dosing of the first subject in the US in the third quarter of 2021 and the first subject in Europe in November 2022 at a site in France (https://ibn.fm/weOO6).

The enrollment of the first patient in Spain affirms CNS’ commitment to the study and highlights the years of meticulous planning and execution which have culminated in this huge milestone for the company. It followed the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland, all in a move to better understand the treatment of recurrent GBM.

CNS believes Berubicin to be the first anthracycline to appear to cross the blood-brain barrier. While it has shown incredible potential in the treatment of brain-related illnesses, CNS is exploring its potential for the treatment of other diseases, including metastatic pancreatic and ovarian cancers, as well as CNS lymphomas. By doing so, it looks to tap into the growing brain tumor therapeutics market, which is expected to hit $3.4 billion by 2025, up from $2.25 billion in 2019.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• McEwen Mining, a diversified gold and silver producer with operations in the Americas, owns 52% of McEwen Copper and its Los Azules Project in San Juan, Argentina
• McEwen Copper has reported initial exploration and solid delineation results that have similarities to world class porphyry copper deposits in Chile and Peru
• Exploration results (AZ22174) include 1,052 m of continuous copper mineralization to the end of the hole implying extensions of the deposit to the north and at depth
• Delineation results (AZ23191) revealed copper continuity in the core of the deposit, with some of the highest grades reported to date
• McEwen Copper will release an update of results from its extensive drill program of more than 25,000 m in 75 new holes in the near future

McEwen Copper, the base metal developer 52% owned by McEwen Mining (NYSE: MUX) (TSX: MUX), recently reported infill and step-out exploration drilling results at its 100%-owned Los Azules Project in Argentina. Los Azules, a large porphyry copper-gold-silver deposit with considerable growth potential, has many characteristics comparable to world-class deposits in South America. Interestingly, while its ultimate depth and lateral extent are unknown, the project is already ranked as the world’s 9th largest undeveloped copper project (https://ibn.fm/7ettb).

The reported assay results include one drill hole from exploration and one from the delineation. The exploration program targets increasing known mineralization further to the north and at depth. The delineation program seeks to reduce geological and resource modelling risk prior to a planned 2024 feasibility study. The company’s initial exploration hole, AZ22174, was drilled to a depth of 1,128 m, with visible copper mineralization observed along its entire core length during logging. Assaying results include a 1,052 m intercept averaging 0.29% copper (“Cu”), 0.05 g/t gold (“Au”), and 1.0 g/t silver (“Ag”). Within this intercept a high-grade core returned 480 m of 0.42% Cu and also included a 26 m sub-interval of early mineral porphyry and quartz veinlets averaging 1.46% Cu (https://ibn.fm/Xsg9w).

Mineralization along the drill hole is more prevalent below 500 m, where more than 66% of the overall contained copper in the hole (480 m grading 0.42% Cu) resides. According to McEwen Copper, the results from AZ22174 reinforce its belief in deposit extensions likely occurring to the north and at depth.

“Exciting results in hole AZ22174 highlight the potential of exploration to create additional value for McEwen Copper, and continuity of mineralization in the infill program is de-risking our mineral resource.” commented Michael Meding, Vice President and General Manager of McEwen Copper.

Meanwhile, the delineation program continued in hole AZ23191, which lies 50 m north of Section 36 (see Figure 2 of the January 26 press release; https://ibn.fm/5c8Rc) near the center of the deposit. Assay results grading 1.39% Cu over 236 m, including a 42 m sub-interval with grading 2.78% Cu are among the very best intercepts reported on the project to date. Assays along the final 31 m of the hole remain pending. Such a high grade intercept occurring proximal to a lower grade hole in the core of the deposit (AZ22180), is indicative of the structurally controlled nature of mineralization. Overall, grades are highest where structural control is strongest.

The exploration and delineation drilling program restarted in October last year, and covers more than 25,000 m in 75 new holes. The program, which is designed to (a) demonstrate extensions of the Los Azules project to the north, south, and at depth, (b) provide metallurgical, hydrological, and geotechnical data to facilitate mine design, and (c) increase infill drilling to upgrade the Cu, Au, and Ag resource classification to measured and indicated, is on course. Since January 2022 and the third week of February 2023, McEwen Copper had completed more than 30,000 m of drilling. The company expects to release a more comprehensive update of results from the drilling campaign soon.

McEwen Mining is a diversified gold and silver producer with operations in Nevada, Canada, Mexico, and Argentina. The company also has significant exposure to copper through its 52%-owned McEwen Copper, owner of the Los Azules project in Argentina and the Elder Creek project in Nevada.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• Ucore is a company engaged in the exploration for and separation and scalable production of REEs in Canada and the US
• The company is focusing on a section of the REE supply chain where China has taken control of rare earth oxide production: the midstream
• Ucore is focused on finding US-allied friendly feedstocks upstream, processing them, and then feeding them to customers downstream that want to find an ex-China solution to be able to make things work for them
• The company’s RapidSX is a more competitive REE processing technology that improves the efficiency of the conventional solvent extraction process, resulting in better throughput and other allied benefits

Scientists have continuously explored the potential of rare earth elements in various fields, and have long established them as nation-critical. Just recently, a team led by Professor Ranga Dias discovered a new superconducting material that “works at both a temperature and a pressure low enough to actually use it in practical situations,” according to an article in the Independent (https://ibn.fm/SRCOv). The material is made by mixing a rare earth metal called lutetium with hydrogen and a small part of nitrogen and leaving these elements to react for two or three days at high temperatures.

To acquire its superconducting properties, the material, nicknamed ‘reddmatter,’ must be compressed to about 145,000 psi and heated to 20.5°C. But according to the article, these conditions are vastly less intense than other similar materials, which is why Andrew Griffin, the author, believes the material has reached “a breakthrough that scientists have been chasing for more than a century, in making a material that is able to transmit electricity without resistance and pass magnetic fields around the materials.”

‘Reddmatter’ is just the latest example of the potential of rare earth elements (“REEs”), which are currently 17 in total in Mendeleev’s periodic table. REEs are considered strategic resources because they are rare (in that they require significant processing), valuable, non-substitutable, and difficult to imitate. As raw materials, they are indispensable in a wide range of sectors, including energy, agriculture, and national defense, among others (https://ibn.fm/be8xp).

With each passing day, the demand for REEs continues to rise, yet the natural reserves remain limited and largely concentrated in China. In fact, as of December 2022, China accounted for 63% of the world’s REE mining, 85% of REE processing, and 92% of rare earth magnet production, according to Politico magazine (https://ibn.fm/Tfp0q).

However, Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for and separation and scalable production of REEs in Canada and the US, is out to ensure that China’s dominance does not leave vulnerable those North American companies that are particularly reliant on these critical rare earth elements. This comes at a timely juncture, especially considering the degrading China-US relationship.

To achieve this, Ucore is looking at the means of REE processing used in China and trying to find better ways to do that in North America, thereby taking back control of the supply chain. According to the company’s November 2022 investor presentation, the REE supply chain comprises three main segments – the upstream, midstream, and downstream – with each made up of two supply nodes. The upstream consists of REE ore and REE mineral concentrate production, the midstream features the production of REE chemical concentrate and REE oxides, and the downstream is made up of the manufacture/production of REE metals and alloys and REE-based magnets and components (https://ibn.fm/ECbL3).

“Where Ucore is very focused on is in the middle of this supply chain market. It’s the midstream. It’s the part where China has taken control of rare earth oxide production, which then gets turned into metals and alloys and eventually permanent magnets. And once you have permanent magnets, you’re controlling the entire industry,” said Ucore Chairman and CEO Pat Ryan in a presentation published on the company’s website (https://ibn.fm/ONpB5).

“So, Ucore is focused on finding US-allied friendly feedstocks to the left – upstream – [processing the feedstocks], and then feeding them into customers downstream that want to find an ex-China solution to be able to make things work for them. That mid-market is where China has taken control. That’s where Ucore will make a difference. No one’s doing what you’re doing. We are taking advantage of recreating the mid-market in North America, which is crucial to recreating the supply chain,” Ryan continued.

Ryan further stated that North American OEMs are looking for ex-China solutions, which has brought them to its doorstep; as a result, Ucore is engaged in ongoing discussions with them. UURAF, therefore, plans to leverage strategic partnerships with these North American companies, both on the upstream and downstream ends of the supply chain spectrum, to disrupt China’s dominance.

Meanwhile, the company has “westernized” REE processing, making it more competitive. In May 2020, Ucore acquired Innovation Metals Corp., which has innovated the RapidSX(TM) process, a derivation of the conventional solvent extraction (“SX”) separation and recovery process. RapidSX improves the efficiency of SX through physical means, resulting in better throughput and, consequently, a smaller plant footprint, lesser reagent use, lower capital expenditure, and lower energy consumption.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Fr8Tech aims to revolutionize the commercial trucking industry by introducing logistics and transportation technology catered to moving freight within the USMCA region more efficiently and cost-effectively
• The update includes several new features and improvements, including real-time tracking and monitoring of shipments, which will allow shippers to see exactly where their freight is at all times and receive notifications for delays
• Fr8Tech projects that during 2023, it will hit revenues between $36 million and $42 million, compared to preliminary 2022 revenue of approximately $26 million to $27 million

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process, providing an AI and machine-learning platform, Fr8App, for B2B cross-border shipping in USMCA regions, has announced the launch of a major update for its transportation management system, Fr8TMS 3.0. This platform upgrade aims to revolutionize the commercial trucking industry by introducing advanced logistics and transportation technology to move freight within the USMCA region, focusing on cross-border shipping.

According to data from the U.S. Department of Transportation, the ongoing disruption in U.S.-Chinese trade relations has strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion (https://ibn.fm/XO12n). Fr8Tech’s wholly-owned Mexican subsidiary aligned automation of its Fr8App platform with Mexico’s CFDI 4.0, a new standard for digital tax receipts which became mandatory in January 2023.

“We are excited to introduce this new update to the Fr8TMS, which will revolutionize the commercial trucking industry. The new features and improvements will make it easier for shippers to move their freight, and it will also benefit carriers and drivers by connecting them with shippers looking to move their freight,” said Javier Selgas, CEO of Fr8Tech (https://ibn.fm/Cirj8).

The update for Fr8TMS includes several new features and improvements, including better real-time tracking and monitoring of shipments, which will allow shippers to see exactly where their freight is at all times – receiving notifications if there are delays or issues with the shipment. A new rating system for carriers will allow shippers to compare the performance of multiple carriers to make better-informed decisions about which carrier to use for their shipments.

Fr8Tech’s Fr8App platform and mobile app connect shippers, carriers, and drivers – making it easier for freight to be moved within the USMCA region. It boasts a streamlined booking process, improved search and filtering options, and the new transportation management system for easy access, making it easier for shippers to find and book the right freight at the right price.

Fr8App is easy to use and begins with creating an account on the company’s website. Once registration is completed, an Fr8App representative reaches out to ensure that all necessary information has been provided and to provide support in setting up the initial shipment. Once an account has been created, the next steps include the following:

• Logging into the online account and scheduling the shipment, which includes the pickup and delivery locations, generating a cost estimate. Once approved, the shipment can be confirmed with a single click
• Once the shipment is confirmed, truck drivers can view the shipment information and choose to accept the job. The driver then collects the cargo at the agreed-upon time, and the shipper receives regular updates and tracks the shipment as it progresses
• The truck driver will take pictures to confirm successful delivery at the final destination. Shippers can reserve loads up to two weeks in advance, with a minimum notice period of 24 hours

Fr8Tech projects that during 2023, it will hit revenues between $36 million and $42 million, compared to preliminary 2022 revenue of approximately $26 million to $27 million. The Fr8App team is dedicated to the continuous improvement and evolution of its platform to meet the needs of its customers. The company is confident that the new update will make Fr8App more valuable for shippers, allowing them to save time and money on their freight operations.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform at www.Fr8.app.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

121 Mining Investment Las Vegas (28-29 March) offers junior resource companies and investors from the mining spectrum a unique platform to connect and network for future growth and key business prospects.

The CEOs from 55 vetted natural resource companies are heading to bustling Las Vegas to present project updates and meet over 150 investors for two days of 1-2-1 meetings.

These meetings will run alongside a content-packed conference schedule, covering topics such as the energy transition, the gold outlook, precious metals investment strategies, uranium, and the impacts of megatrends on metals and mining investing.

Qualified investors are able to attend the event free of charge. Attending investors will not only be able to schedule 1-on-1 meetings with leading mining company CEOs and hear analysts and stock pickers present, they will also be able to enjoy the fantastic networking Las Vegas has to offer. All attendees are also invited to 121 Las Vegas networking drinks at Circa’s Legacy Club rooftop bar on March 28th from 17:00.

If you are unfamiliar with 121 Group, they are the world’s leading dedicated mining investment event series, organising summits worldwide. Their portfolio includes events in London, New York, Cape Town, Hong Kong, Sydney, Melbourne, Singapore and Las Vegas.

Whether you are an investor looking for exciting new projects, or a mining company hoping to raise capital and make new connections, 121 Mining Investment Las Vegas is THE premier forum to make it happen.

To learn more, please visit https://ibn.fm/KAfYA

DealFlow Events is pleased to announce its upcoming event, The Venture Debt Conference, taking place March 31 in New York City. This conference couldn’t have come at a better time for executives interested in loan strategies for VC-backed and emerging growth companies. This event will discuss in detail the effects that the Silicon Valley Bank failure will have on the venture debt market by the top experts in the space.

The use of venture debt has been gaining in popularity as emerging growth companies grapple with a more challenging market for equity venture capital. Many debt products such as term loans, revenue-based financing, receivables financing, and equipment financing fall under the broad moniker of venture debt, but despite the popularity of these products, for many, venture debt remains an unfamiliar form of financing.

Hosted by DealFlow Events, this full-day forum addresses the growing interest in using venture debt to complement venture capital and to discuss alternative financing with companies unfamiliar with these investment strategies. Companies interested in obtaining venture debt can attend the event for free.

The conference will feature speakers and panel discussions from industry experts, including Troy Zander, Barnes & Thornburg, John Borchers/Decathlon Capital, Spring Hollis/Star Strong Capital, John Markell/Armentum Partners, Steve Kietz/Reliant Funding, Dolph Hellman/Orrick, Thomas Ritchie/Biz2Credit, Catherine Jhung/Hercules Capital, Melissa Winder/Lighter Capital, Kai Tse/Structural Capital, David Spreng/Runaway Growth Capital, Alidad Vakili/Foley & Lardner, Peter Frank/i80 Group, Dan Devorsetz/Horizon Technology Finance, David Teten/Versatile Venture Capital, and Brent Bertino/Trinity & ESW Capital.

Corporate sponsors of The Venture Debt Conference include Armentum Partners, Barnes & Thornburg, Horizon Technology Finance, DLA Piper, RRBB Accounting & Advisors and IBN (InvestorBrandNetwork).

Attendees will have the opportunity to learn about the latest trends in the venture debt market, as well as gain valuable insights into fundraising strategies. In addition to the conference program, attendees will also have access to a variety of networking opportunities, including a networking reception and one-on-one meetings with venture debt providers.

About The Venture Debt Conference

The Venture Debt Conference addresses the growing interest in using venture debt to complement venture capital while offering a forum to discuss alternative financing to companies that may not be familiar with these investment strategies.

To learn more, please visit https://ibn.fm/7LYir

Contact: Charlie Napolitano (516) 876-8006 ext. 20 charlie@dealflowevents.com

• Cybersecurity services and technology provider SideChannel Inc. is a provider of expert “virtual” chief information security officer (“vCISO”) guidance to SMBs that can’t sustain a full-time CISO as part of their staff budget
• The need for CISO guidance is apparent in the trillions of dollars lost worldwide to cyber attacks on a yearly basis and the ever-evolving nature of cyber attack threats
• SideChannel also provides a microsegmentation software-as-a-service (“SaaS”), branded Enclave, that is available to clients via subscription or as a managed service offering, to help strengthen company computer systems against invasive attacks
• SideChannel is celebrating its ability to retain its clientele revenue on an ongoing year-to-year trailing basis, the company’s CFO stated in a recent company webcast

As companies assess their security needs to avoid severe damage to their budget line and reputation, cybersecurity needs are taking on an ever greater emphasis. An estimated 30,000 websites are hacked daily, with the cost of cyber attacks placed at $6 trillion last year, underlining the reality of a malicious environment for business activities online (https://ibn.fm/fR7i8).

While businesses routinely are identifying cyber threats to their operations, a serious question they need to ask themselves is just how many threats are currently undetected, as risk management company C2’s CEO Jonathan Wood recently noted in a CPO Magazine article. It’s important to consider that many cybercriminals will breach a company’s infrastructure, and then lurk in the shadows until the most opportune moment arises for launching a full-scale attack (https://ibn.fm/FIKiC).

Detecting hidden cyber threats can be complicated and easily overlooked until they strike and damage is done.

“We’re seeing attacks increase. We’re seeing the costs of these attacks increase over time. And we’re seeing (the nature of the attacks) change,” SideChannel (OTCQB: SDCH) CEO Brian Haugli stated in a live company webcast recently.

SideChannel is a cybersecurity services and technology provider whose key service is providing virtual chief information security officers (“vCISOs”) on contract to small and medium-sized businesses (“SMBs”) that don’t have a budget capacity to hire their own full-time CISOs.

“Our revenue is really built on relationships,” CFO Ryan Polk added during the webcast (https://ibn.fm/MWldH). “The vast majority of the work that we do for our clients has an ongoing nature to it. … We are retaining about 73 percent on a trailing 12-month basis of the revenue that we generated one year ago.”

Although vCISOs might be described somewhat dismissively as rent-a-CISOs, SideChannel’s cybersecurity experts are presented to clients as guidance providers who can work in the boardroom alongside the companies’ leading officers.

“The cybersecurity profession is now akin to legal, and accounting, and insurance,” Haugli said during the webcast. “When we look inside organizations at the enterprise level we see the CISO right there with HR (Human Resources), and GC (General Contracting), and Internal Audit and other C-suite members for a reason. Because that’s how important it is for that organization’s success to address cybersecurity as an operational risk at an enterprise level. And our clients are seeing it, and they’re realizing the value that they’re getting out of it by working with us.”

SideChannel also has developed a microsegmentation security product named Enclave that it offers either as a software-as-a-service (“SaaS”) tool on a subscription basis, or as a managed service offering that exceeds what is otherwise available throughout the industry.

“Our (product) focus right now is to continue Enclave development and the roadmap we’ve built out for that,” Haugli said. “We are looking at new features around protecting endpoint devices with a more cloud-based and scalable capability. So we’re going to continue to develop around Enclave, adding new features and capabilities that make sense for how Enclave is structured — based … on what we’re seeing in our clients, what we’re hearing from our CISOs and what types of attacks or attack surface is out there.”

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Lexaria Bioscience is a global innovator in drug delivery platforms
• The company has been developing and commercializing patented DehydraTECH(TM), a technology that has been shown to increase the bioavailability of fat-soluble active molecules, improve the speed of onset and provide other benefits across multiple applications
• Lexaria has undertaken numerous R&D programs in an effort to build relationships with prospective corporate partners to out-license the technology or to form other profitable corporate relationships
• The company owes its achievements to its focus on R&D and the guidance provided by its highly experienced leadership, including CEO Chris Bunka, President John Docherty, as well as a dedicated and active board of directors

Lexaria Bioscience’s (NASDAQ: LEXX) path to becoming a global leader and innovator in drug delivery traces its origins to 2014, when CEO Chris Bunka redirected the company to its current business, focusing on the research and development (“R&D”) of the delivery of lipophilic active molecules based on its patented DehydraTECH(TM) technology. Protected by 28 granted patents worldwide, with many more pending around the world, the technology can lay claim to the potential of disrupting the drug delivery space as it is known today.

Typically, a drug delivery system is a formulation or a device that enables the introduction of a therapeutic substance into the body. It is specifically designed to improve the substance’s efficacy and safety by controlling the rate, time, and place of release of drugs in the body. Over the years, drug delivery scientists have been on a quest to improve the existing systems, leading to the introduction of nanoparticles, emulsifiers, and microalgae-based oral microcarriers (https://ibn.fm/V9lDo), just to name a few.

This quest is informed in large part by the shortcomings of existing systems. And as Lexaria has established, these systems are not particularly effective at delivering as much of the drug as possible into the bloodstream for use by the body; to put it more technically, they have low bioavailability. Additionally, the company has observed that drugs, especially fat-soluble active pharmaceutical ingredients (“APIs”), take a considerable time to start working when delivered using the existing systems.

In light of the evident shortcomings, Lexaria has been developing DehydraTECH, a platform technology that enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical formats. DehydraTECH, the company explains on its website, is an additional step that is easily and seamlessly incorporated into the formulation and manufacturing process of existing or new products.

“This step involves mixing the active ingredients as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors,” the website continues (https://ibn.fm/jsri8).

The result? The improved and more rapid absorption of active molecules into the bloodstream and brain tissue. This benefit, according to Lexaria, stems from the fact that DehydraTECH works symbiotically with existing physiological systems, thus enabling better bioavailability and bio-absorption. Another result is that fat-soluble molecules processed using the DehydraTECH technology become masked to oral and olfactory receptors, rendering them mostly flavorless and odorless.

Since 2014, Lexaria has undertaken multiple R&D programs covering such DehydraTECH-processed active molecules as nicotine, cannabidiol (“CBD”), and antiviral drugs (https://ibn.fm/cObdA). These initiatives have not only proven the above results to be true but also opened up additional commercialization opportunities.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world, for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” Bunka wrote in the annual CEO letter to shareholders published January 2023 (https://ibn.fm/FOOVZ). “It is a direct result of our positive R&D programs that, as 2023 begins, we are actively involved in several sets of ongoing discussions and due diligence proceedings with potential corporate partners with a goal of collaboration, DehydraTECH out-licensing, or other corporate relationships.”

Additionally, the company is working toward an Investigational New Drug (“IND”) application that will seek FDA’s approval to undertake Phase 1(b) registered trial evaluating DehydraTECH-CBD as a potential treatment for hypertension. The study, which will seek to uncover the safety and tolerability of the formulation, is expected to begin this year.

Lexaria’s accomplishments so far can be attributed largely to the guidance of CEO, Chairman and Director Chris Bunka, President and Director John Docherty, and the company’s board of directors with members who have decades of experience in public and private businesses.

For instance, Dr. Catherine C. Turkel, Pharm.D, Ph.D., has over 20 years’ experience as an executive in startup and mid-size pharma or biotech companies. Having previously served as Founder and CEO of Nezee Therapeutics and President and R&D Head at Novus Therapeutics, since renamed Eledon Pharmaceuticals (NASDAQ: ELDN), she has formulated registration and commercial strategic plans and spearheaded global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 (https://ibn.fm/o3FLS). Her experience will, therefore, be invaluable as Lexaria conducts its planned FDA clinical trials.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX